25 September 2024 - Neurolixis granted Orphan Medicinal Product Designation for NLX-112 as a Treatment for Spinocerebellar Ataxia

NLX-112 , a highly selective serotonin 5-HT1A receptor agonist, has been granted Orphan Medicinal Product (OMP) Designation by the European Commission for the treatment of Spinocerebellar Ataxia (SCA; approval #EU/3/24/2951). This decision follows a positive recommendation from the Committee for Orphan Medicinal Products (COMP). SCA is a group of rare genetic disorders, most notably Machado-Joseph Disease (SCA3) , which leads to progressively worsening neurological symptoms such as clumsiness, muscle weakness, and tremors, often resulting in severe disability. The OMP designation for NLX-112 was awarded following a successful collaboration between Neurolixis and Professor Patricia Maciel's team at the University of Minho in Portugal. This partnership, funded by the U.S. Department of Defense, showed that NLX-112 significantly reduces motor dysfunction in a transgenic mouse model of SCA3. 👉 Full Press Release : https://t.ly/hUL6R   👉 European Medicines Agency Announcement : https://t.ly/qkjCd 👉 More on Spinocerebellar Ataxias : https://t.ly/UoIFL 👉 Info on NLX-112 and Related Compounds : https://t.ly/hCB8y

The release as fetched from its publisher. neurolixis.com ↗